2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value
2015
Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.Peer-Reviewed Original ResearchHigh-dose influenza vaccineHigh-dose vaccinePlasma cell disordersNovel vaccination strategiesProtective HAI titersCell-mediated immunityMultiple myeloma patientsNovel vaccine strategiesInfluenza vaccineVaccination strategiesSignificant unmet needInfluenza vaccinationHAI titersPCD patientsCell disordersFlu seasonSecondary endpointsSeroprotection ratesDose vaccineMyeloma patientsVaccine strategiesFlu infectionUnmet needInfection rateGrade 2 adverse events